Opt-Out Syphilis Screening in ED Improves Screening, Diagnosis
By Lori Solomon HealthDay Reporter
FRIDAY, Sept. 13, 2024 -- Implementation of opt-out emergency department syphilis screening leads to a dramatic increase in screening and diagnosis, especially among pregnant individuals, according to a study published online Sept. 10 in Open Forum Infectious Diseases.
Kimberly A. Stanford, M.D., from University of Chicago, and colleagues examined trends in syphilis screening and diagnosis before and after implementation of an opt-out emergency department syphilis screening intervention in May 2019.
The researchers found that syphilis screening increased from 3.6 to 24.4 percent of encounters. Presumed active syphilis infection (PAI) increased 288 percent during the study period, from 161 patients (3.1 percent of those screened) to 624 patients (1.7 percent of those screened). Similarly, the proportion of women with PAI increased from 25.6 to 42.5 percent, despite no change in the proportion of women screened. Following implementation, 23.6 percent of PAI were tested for a urogenital sexually transmitted infection (STI) in the emergency department and 9.0 percent presented with symptoms of an STI by diagnosis code. Screening increased from 5.9 to 49.9 percent of encounters among pregnant people, and syphilis diagnosis increased 750 percent (from two cases to 15).
“Opt-out screening will be an important strategy in the effort to address the syphilis epidemic,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-14 06:00
Read more
- Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
- Protega Pharmaceuticals Receives FDA Approval for RoxyBond (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
- Measures of Social Support Linked to Cancer Screening
- USPSTF Recommends Providing Interventions to Support Breastfeeding
- Even Hardcore Smokers May Quit If Given Right Tools, Study Finds
- America's Epidemic of STDs May Finally Be Slowing
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions